Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in…
$700.22+0.11%
报价 2026-11-13
市值
$259.44B
EV
$208.61B
PE (TTM)
26.8x
预期 PE (FY2026)
27.7x
52 周区间距高点 -3.0%
$438.34$721.63
筛选结果
pipeline · 2026-11-13Filter✗ 高增长✗ Cheap✗ GARP
does not hit growth, cheap, or GARP pool
爆发潜力
2026-11-13未命中✗ 收入线✗ EPS 线
| 财年 | 收入倍数 | EPS | PE |
|---|---|---|---|
| FY+22027-12 | 1.1x | 24.72 → 27.75（1.1x） | 25.2 |
| FY+32028-12 | 1.1x | 24.72 → 30.63（1.2x） | 22.9 |
毛利率 39% · TTM 收入 $47351M · 基数 EPS 24.72（调整后）
电话会信号
辅助标签Q3 20262026-10-21
扩产需求加速AI 词频高上调指引
指引 上调
信心 5
分析师 4
“We are raising our guidance for the full year on the top and bottom line, reflecting another quarter of strong operational performance.”
原文引用（3）
- 扩产：incrementally supporting the scale-up of new capacity in our Pharma Services business
- 需求加速：the activity that we saw step up in Q2 in our end markets continued
- 上调指引：We are raising our guidance for the full year on the top and bottom line
蓝色标签在暴涨研究中略有区分度；悬停查看口径。
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| TMOThermo Fisher Scientific Inc. | $259.44B | +0.1% | +8.4% | 39.5% | 26.8x | 18.2x | 34.2x | |
| MRKMerck & Co., Inc. | $364.27B | +0.6% | +3.7% | 73.5% | 121.5x | 30.7x | 23.5x | |
| NVSNovartis AG | $303.12B | +0.2% | – | 76% | 20.2x | 13.5x | – | |
| AZNAstraZeneca PLC | $286.06B | +0.0% | – | 78.2% | 27.5x | 15.4x | – | |
| AMGNAmgen Inc. | $251.89B | -0.3% | +8.4% | 70.5% | 24.4x | 12.5x | 26.3x | |
| ABTAbbott Laboratories | $187.95B | +1.2% | +11.9% | 57.1% | 40.9x | 22.5x | 28.3x | GARP |
| NVONovo Nordisk A/S | $183.52B | +2.4% | – | 78.2% | 10.3x | 7.2x | – | Cheap |
| DHRDanaher Corporation | $163.94B | +0.4% | +7.0% | 60.9% | 37.2x | 21.3x | 28.6x | |
| ISRGIntuitive Surgical, Inc. | $153.77B | +0.8% | +19.9% | 68.4% | 59.4x | 46.0x | 42.7x | |
| 同行中位数 | – | – | +8.4% | 72% | 32.4x | 18.4x | 28.3x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。